- Home
- Publications
- Publication Search
- Publication Details
Title
ATRX immunostaining predicts IDH and H3F3A status in gliomas
Authors
Keywords
Glioma, ATRX, IDH, H3F3A, Astrocytoma, Oligodendroglioma
Journal
Acta Neuropathologica Communications
Volume 4, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-06-16
DOI
10.1186/s40478-016-0331-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas
- (2016) Masako Ikemura et al. HISTOPATHOLOGY
- IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO
- (2015) David E. Reuss et al. ACTA NEUROPATHOLOGICA
- Predictors of preoperative and early postoperative seizures in patients with intra-axial primary and metastatic brain tumors: A retrospective observational single center study
- (2015) Marco Skardelly et al. ANNALS OF NEUROLOGY
- Glioblastomas, astrocytomas and oligodendrogliomas linked to Lynch syndrome
- (2015) C. Therkildsen et al. EUROPEAN JOURNAL OF NEUROLOGY
- Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas
- (2015) Ekkehard Hewer et al. HISTOPATHOLOGY
- Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial
- (2015) Hendrikus J. Dubbink et al. NEURO-ONCOLOGY
- Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
- (2015) Jeanette E. Eckel-Passow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
- (2015) Yuchen Jiao et al. Oncotarget
- Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
- (2015) Kasthuri Kannan et al. Oncotarget
- ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples
- (2015) Jinquan Cai et al. Oncotarget
- Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma
- (2014) Benedikt Wiestler et al. ACTA NEUROPATHOLOGICA
- Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma
- (2014) Felix Sahm et al. ACTA NEUROPATHOLOGICA
- ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma
- (2014) David E. Reuss et al. ACTA NEUROPATHOLOGICA
- Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas
- (2014) Christine Haberler et al. CLINICAL NEUROPATHOLOGY
- Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM
- (2014) Pankaj Pathak et al. JOURNAL OF NEURO-ONCOLOGY
- ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis
- (2013) Benedikt Wiestler et al. ACTA NEUROPATHOLOGICA
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
- (2013) A. Sottoriva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations
- (2012) Xiao-Yang Liu et al. ACTA NEUROPATHOLOGICA
- Molecular and Morphologic Correlates of the Alternative Lengthening of Telomeres Phenotype in High-Grade Astrocytomas
- (2012) Doreen N. Nguyen et al. BRAIN PATHOLOGY
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
- (2012) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
- (2012) Jeremy Schwartzentruber et al. NATURE
- Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma
- (2011) Jens Schittenhelm et al. ACTA NEUROPATHOLOGICA
- Altered Telomeres in Tumors with ATRX and DAXX Mutations
- (2011) C. M. Heaphy et al. SCIENCE
- DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
- (2011) Y. Jiao et al. SCIENCE
- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
- (2010) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- Update on molecular findings, management and outcome in low-grade gliomas
- (2010) T. David Bourne et al. Nature Reviews Neurology
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
- (2009) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
- (2009) Takuya Watanabe et al. AMERICAN JOURNAL OF PATHOLOGY
- Novel Molecular Stereotactic Biopsy Procedures Reveal Intratumoral Homogeneity of Loss of Heterozygosity of 1p/19q and TP53 Mutations in World Health Organization Grade II Gliomas
- (2009) Niklas Thon et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More